A single-dose, open-label study of TX000045 in patients with CpcPH or IpcPH and HFpEF
Latest Information Update: 12 Sep 2025
At a glance
- Drugs TX-000045 (Primary)
- Indications Cardiovascular disorders; Pulmonary hypertension
- Focus Adverse reactions
- Sponsors Tectonic Therapeutic
Most Recent Events
- 12 Sep 2025 New trial record